Large-scale validation of skin prion seeding activity as a biomarker for diagnosis of prion diseases
Weiguanliu Zhang,Christina D. Orrú,Aaron Foutz,Mingxuan Ding,Jue Yuan,Syed Zahid Ali Shah,Jing Zhang,Keisi Kotobelli,Maria Gerasimenko,Tricia Gilliland,Wei Chen,Michelle Tang,Mark Cohen,Jiri Safar,Bin Xu,Dao-Jun Hong,Li Cui,Andrew G. Hughson,Lawrence B. Schonberger,Curtis Tatsuoka,Shu G. Chen,Justin J. Greenlee,Zerui Wang,Brian S. Appleby,Byron Caughey,Wen-Quan Zou
DOI: https://doi.org/10.1007/s00401-023-02661-2
IF: 15.887
2024-01-19
Acta Neuropathologica
Abstract:Definitive diagnosis of sporadic Creutzfeldt–Jakob disease (sCJD) relies on the examination of brain tissues for the pathological prion protein (PrP Sc ). Our previous study revealed that PrP Sc -seeding activity (PrP Sc -SA) is detectable in skin of sCJD patients by an ultrasensitive PrP Sc seed amplification assay (PrP Sc -SAA) known as real-time quaking-induced conversion (RT-QuIC). A total of 875 skin samples were collected from 2 cohorts (1 and 2) at autopsy from 2–3 body areas of 339 cases with neuropathologically confirmed prion diseases and non-sCJD controls. The skin samples were analyzed for PrP Sc -SA by RT-QuIC assay. The results were compared with demographic information, clinical manifestations, cerebrospinal fluid (CSF) PrP Sc -SA, other laboratory tests, subtypes of prion diseases defined by the methionine (M) or valine (V) polymorphism at residue 129 of PrP, PrP Sc types (#1 or #2), and gene mutations in deceased patients. RT-QuIC assays of the cohort #1 by two independent laboratories gave 87.3% or 91.3% sensitivity and 94.7% or 100% specificity, respectively. The cohort #2 showed sensitivity of 89.4% and specificity of 95.5%. RT-QuIC of CSF available from 212 cases gave 89.7% sensitivity and 94.1% specificity. The sensitivity of skin RT-QuIC was subtype dependent, being highest in sCJDVV1-2 subtype, followed by VV2, MV1-2, MV1, MV2, MM1, MM1-2, MM2, and VV1. The skin area next to the ear gave highest sensitivity, followed by lower back and apex of the head. Although no difference in brain PrP Sc -SA was detected between the cases with false negative and true positive skin RT-QuIC results, the disease duration was significantly longer with the false negatives [12.0 ± 13.3 (months, SD) vs. 6.5 ± 6.4, p < 0.001]. Our study validates skin PrP Sc -SA as a biomarker for the detection of prion diseases, which is influenced by the PrP Sc types, PRNP 129 polymorphisms, dermatome sampled, and disease duration.
pathology,neurosciences,clinical neurology